+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 22 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of opevesostat combined with daily corticosteroids compared to alternative hormonal agents abiraterone acetate or enzalutamide in adults with metastatic castration-resistant prostate cancer mCRPC who have previously received one next-generation hormonal agent. This Phase 3 randomized study aims to determine if opevesostat improves overall survival in participants with or without androgen receptor ligand binding domain mutations. Participants in the experimental group will take opevesostat 5 mg orally twice daily along with dexamethasone 1.5 mg and fludrocortisone acetate 0.1 mg once daily continuously until their disease progresses. Hydrocortisone is available as a rescue medication. The comparison group will receive abiraterone 1000 mg once daily plus prednisone 5 mg twice daily or enzalutamide 160 mg once daily until disease progression. Treatments are oral medications administered daily. During the study, participants will be monitored for overall survival up to about 82 months, along with other outcomes such as progression-free survival, time to new treatments, response rates, pain progression, and quality of life assessments. Safety will be tracked by recording adverse events and treatment discontinuations. The total study duration may last up to nearly seven years, including follow-up assessments to evaluate long-term effects and benefits.

Age: 18Years +All GendersPhase 3
330 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TAR-210 compared to intravesical chemotherapy in treating high-risk non-muscle-invasive bladder cancer HR-NMIBC. This Phase 3 study focuses on disease-free survival, which is the length of time participants live without signs or symptoms of cancer returning or worsening. The study targets patients with specific FGFR genetic alterations who have previously received BCG treatment but remain at high risk for cancer recurrence. Participants are randomly assigned to one of two groups Group A will have the investigational drug TAR-210 placed inside the bladder on Day 1 and continue treatment for about two years. Group B will receive intravesical chemotherapy with either mitomycin C or gemcitabine weekly for 4 to 6 doses, followed by monthly maintenance for up to one year, with an optional second year of maintenance depending on the investigators decision. All treatments are delivered directly into the bladder. Throughout the study, participants will have regular assessments including monitoring for cancer recurrence, progression, and overall survival for up to five years. Researchers will collect safety data such as adverse events and changes in laboratory tests and vital signs. Quality of life will be measured using specific questionnaires at multiple time points. The study involves ongoing visits and evaluations to closely observe treatment effects and participant well-being over the long term.

Age: 18Years +All GendersPhase 3
115 locations
E

Actively Recruiting

Researchers are comparing the disease-free survival in adults with intermediate-risk non-muscle invasive bladder cancer IR-NMIBC who receive either TAR-210 or the investigators choice of intravesical chemotherapy. The study focuses on participants with susceptible FGFR alterations and aims to evaluate the efficacy and safety of these treatments over approximately four years. This is a phase 3 randomized trial sponsored by Janssen Research & Development, LLC. Participants are randomly assigned to one of two groups. Group A receives TAR-210, which is inserted into the bladder on Day 1 and removed after 12 weeks this procedure is repeated every 12 weeks for about one year. Group B receives intravesical chemotherapy with mitomycin C MMC or gemcitabine, chosen by the investigator. Chemotherapy is given once weekly for 4 to 6 doses, followed by a maintenance phase lasting at least 6 months and up to one year. Throughout the study, participants undergo multiple cystoscopies and tissue assessments to monitor for recurrence or progression of bladder cancer. Researchers measure disease-free survival, time to next treatment, recurrence-free survival, progression-free survival, adverse events, overall survival, and quality of life using standardized questionnaires. Safety is monitored from the first dose through 30 days after the last dose. The total participation period spans about four years and two months for comprehensive evaluation.

Age: 18Years +All GendersPhase 3
193 locations
A

Actively Recruiting

Non-muscle-invasive bladder cancer NMIBC is a type of bladder tumor that affects the inner lining of the bladder without invading the muscle layer. This research aims to collect and analyze real-world data on how NMIBC is managed and followed up in clinical practice across France. The study seeks to assess the performance of urine tests used to detect tumor recurrence and to understand variations in treatment and patient outcomes. The study is observational and involves collecting medical data from patients being monitored for NMIBC, including results from urine biomarker tests done before biopsies or resections. Urologists participating in the French Urology Association will record findings from regular bladder endoscopic exams and urine test results during routine care visits. Data analysis will focus on the accuracy of urine tests in predicting tumor recurrence and how this varies by tumor characteristics and prior treatments. Participants will have their medical history, treatments, and urine test results entered into a registry at enrollment. During follow-up visits scheduled as part of their personalized care, data on bladder exams and urine tests will be collected. Researchers will evaluate outcomes such as recurrence-free survival and the diagnostic value of urine biomarkers over a five-year period. The study plans to include around 8,000 patients over six years to improve understanding of NMIBC management and follow-up.

Age: 18Years +All Genders
44 locations
S

Actively Recruiting

This research aims to evaluate the use of digital tools in dentistry to improve the detection of dental conditions in adults. It compares the standard real-life examination by practitioners, which combines clinical and radiographic assessments, with examinations based on imaging results from digital devices. The study follows up on previous research that provided recent insights into adult patients oral health and care needs. The study involves digital imaging technologies such as intraoral scanners optical impression cameras, panoramic radiography orthopantomogram, and Cone Beam Computed Tomography CBCT. These tools provide 3D images and detailed views of dental structures, potentially offering more systematic and rapid clinical data collection. Radiographs are only performed when medically justified, and there are no deviations from standard care. Participants attend a single study visit where data is collected through clinical examination and imaging results. Researchers will assess various dental conditions, including the number of decayed, missing, or filled teeth, the extent and location of carious and wear lesions, dental restorations, periodontal involvement, and endodontic status. The study focuses on improving the quality and completeness of diagnostic information to support better treatment planning.

Age: 18Years +All Genders
22 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining pembrolizumab and capecitabine as a post-operative treatment for patients with triple negative breast cancer TNBC who have residual disease after receiving neoadjuvant chemotherapy with pembrolizumab. This Phase II trial aims to measure invasive disease-free survival over two years in this patient group, comparing the investigational treatment to a standard care cohort treated with pembrolizumab alone. Participants in the experimental arm will receive pembrolizumab at a fixed dose of 200 mg intravenously every three weeks for a total of nine cycles during the adjuvant phase. Capecitabine tablets will be taken orally at 1250 mgm twice daily for 14 days followed by 7 days off, repeated for eight cycles, with dose reduction during radiotherapy if needed. Local radiotherapy will be given as per standard practice when indicated. An external cohort receiving standard care pembrolizumab after surgery will be observed for comparison. During the study, participants will undergo assessments to monitor survival outcomes including invasive disease-free survival, overall survival, and distant disease-free survival for up to 3.5 years. Safety will be evaluated by tracking acute and late toxicities throughout the study period. Participants will have laboratory tests, tumor tissue analysis, and clinical examinations as part of their follow-up. The trial runs until August 2028 and includes regular visits and monitoring to evaluate treatment effects and safety.

Age: 18Years +All GendersPhase 2
20 locations
P

Actively Recruiting

Researchers are studying the use of ribociclib, a CDK46 inhibitor, in women with early hormone receptor-positive HR and HER2-negative breast cancer who are at intermediate risk of cancer recurrence. The study aims to see if patients can avoid chemotherapy, which has significant side effects, by using ribociclib along with hormone therapy after surgery. This phase III trial builds on the NATALEE study, which showed that ribociclib added to hormone therapy improved survival free of invasive disease in similar patients. Participants will be randomly assigned to one of two groups one receiving ribociclib plus endocrine hormone therapy, and the other receiving chemotherapy followed by ribociclib and endocrine therapy. Ribociclib treatment lasts for three years, and chemotherapy is given before starting ribociclib and hormone treatment. The trial aims to compare the outcomes of chemotherapy de-escalation versus standard treatment in this patient group. During the study, participants will attend scheduled visits for treatment and monitoring, including laboratory tests, heart monitoring with ECG, and questionnaires about their quality of life. Researchers will track invasive breast cancer-free survival and other outcomes such as overall survival and treatment side effects for up to 12 years. Safety and quality of life assessments will continue during and after treatment to evaluate the long-term effects and benefits of the treatment approaches.

Age: 18Years +FEMALEPhase 3
138 locations
Q

Actively Recruiting

Researchers are evaluating the quality of life in men with favourable intermediate-risk localized prostate cancer who are sexually active. The study compares two treatments total prostatectomy, a surgical removal of the prostate, and focal high-intensity focused ultrasound HIFU, which uses ultrasound energy to target and destroy prostate tumor cells. The aim is to understand how these treatments impact prostate cancer-related quality of life over time. Participants will receive either total prostatectomy or focal HIFU as their cancer treatment. Total prostatectomy involves surgery to remove the prostate gland, while focal HIFU focuses ultrasound waves on the tumor area to destroy cancer cells without surgery. These two groups will be observed in parallel, with no random assignment. Treatments are delivered as part of standard medical care based on the chosen therapeutic strategy. During the study, participants will complete the EPIC-CP questionnaire at 6, 12, and 24 months after treatment to assess their quality of life related to prostate cancer. Researchers will monitor and compare the outcomes between the two treatment groups over this two-year period. The study is sponsored by GCS Ramsay Sant pour lEnseignement et la Recherche and will run until the end of 2028.

Age: 40Years - 75YearsMALEPhase Not Applicable
1 location
R

Actively Recruiting

This research aims to compare the cost-effectiveness of focal high-intensity focused ultrasound F-HIFU treatment versus radical prostatectomy RP in men with favorable intermediate risk localized prostate cancer. The study focuses on patients with non-treated prostate cancer characterized by specific Gleason scores and tumor visibility on MRI, evaluating both treatments from a healthcare system perspective. It is a randomized, pragmatic clinical trial conducted across multiple centers, aiming to provide insights into cancer control and side effect profiles such as urinary, sexual, and digestive outcomes. Participants will be randomly assigned to receive either F-HIFU using the Focal-Oneae device under local or general anesthesia or undergo a radical prostatectomy performed via open, laparoscopic, or robot-assisted surgery under general anesthesia. Randomization is stratified by center and initially equal but later adjusted to a 21 ratio favoring F-HIFU. Treatment is followed by regular monitoring up to 48 months, with data collection enhanced using national health databases to assess costs, mortality, and cancer control without additional patient visits. During the study, men will undergo assessments including urinary and sexual function evaluations, quality of life questionnaires, and survival monitoring at multiple timepoints up to 48 months. The primary outcome focuses on the cost-utility ratio at 24 months, with secondary outcomes including survival rates, preserved life costs, and treatment-related quality of life. Participants are closely followed through clinical visits and data linkage, ensuring comprehensive evaluation of both treatment approaches over time.

Age: 50Years - 75YearsMALEPhase Not Applicable
20 locations

1-10 of 22

1